Clinical Trials Logo
  1. Home
  2. Burkitt's Lymphoma
  3. NCT01859819

Treatment for Advanced B-Cell Lymphoma — REBOOT  

Burkitt's Lymphoma Clinical Trial

Official title:
Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma

Clinical Trial Summary

To safely reduce the burden of therapy in children, adolescents and young adults with mature B-NHL by reducing the number of intrathecal (IT) injections by the introduction of IT Liposomal Cytarabine (L-ARA-C, [Depocyt®]) and reducing the dose of anthracycline (doxorubicin) in good risk patients with the addition of rituximab to the FAB chemotherapy backbone (Immunochemotherapy).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01859819
Study type Interventional
Source New York Medical College
Contact
Status Completed
Phase Phase 2
Start date January 2013
Completion date June 2021
View Details
See also
  Status Clinical Trial Phase
Terminated NCT02145039 - Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases N/A
Completed NCT01516593 - Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma Phase 2
Completed NCT01314014 - Imexon for Relapsed Follicular and Aggressive Lymphomas Phase 2
Active, not recruiting NCT02722668 - UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Phase 2
Completed NCT02661035 - Allo HSCT Using RIC for Hematological Diseases Phase 2
Completed NCT02669017 - Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Phase 1
Completed NCT00412243 - Clofarabine and Cyclophosphamide Combination in Acute Lymphoblastic Leukemia Patients Phase 1/Phase 2
Completed NCT01597778 - Double Cord Versus Haploidentical (BMT CTN 1101) Phase 3
Active, not recruiting NCT04464200 - 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Phase 1
Completed NCT00949741 - Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients N/A
Completed NCT00199082 - Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults Phase 4
Completed NCT01474681 - Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Phase 1/Phase 2
Withdrawn NCT01163201 - T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies Phase 1/Phase 2
Terminated NCT00776373 - Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Phase 1/Phase 2
Completed NCT01809600 - Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults N/A
Completed NCT00807495 - Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma Phase 2
Recruiting NCT01962636 - Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases N/A
Completed NCT01397825 - MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine Phase 1/Phase 2
Completed NCT00388193 - Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma Phase 2
Completed NCT00669877 - Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma Phase 2